Note: The headline of this story was updated Dec. 1, 2022, to correct that the decision to continue the Phase 2/3 clinical trial of fosgonimeton was recommended by an independent data monitoring committee. A Phase 2/3 clinical trial evaluating Athira Pharma’s experimental therapy fosgonimeton (formerly ATH-1017) in people…
The National Institute on Aging has awarded $2.85 million in funding to a research team from the University of Tennessee Health Science Center (UTHSC) to study the role of mitochondria  — cells’ powerhouses — in age-related diseases, such as Alzheimer’s. The five-year funding will support a project called…
Eisai has started submitting data to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in support of an application for approval of its investigational lecanemab (BAN2401) to treat early Alzheimer’s disease. This submission followed the company’s prior assessment consultation with the PMDA, given in advance of an approval application and intended…
A clinical trial application for varoglutamstat, or PQ912, an investigational therapy for Alzheimer’s disease, was approved in China, its developers, Vivoryon Therapeutics and Simcere Pharmaceutical Group, announced. “We are proud to have obtained [China’s Center for Drug Evaluation] CDE approval of our Clinical Trial Application of varoglutamstat…
Get regular updates to your inbox.